Advanced search
Start date

A prospective, single center, randomized study comparing the efficacy and safety of the addition of everolimus to tacrolimus/mycophenolate mofetil/predinisone in kidney transplanted recipients HLA-sensitized


Sensitized patients to HLA (Class I or II PRA e 10%) represents 20-25% of renal transplanted patient. They are usually over immunosuppressed to prevent rejection and therefore develop more infections like CMV disease. There is no current immunosuppressive regimen that addresses the demands for these patients. We hypothesize that adding everolimus, an mTOR inhibitor with different site of action and a role in CMV prevention to the tacrolimus/mycophenolic acid/steroids, we will reduce the incidence of acute rejection and prevent CMV disease. We also do not expect more serious adverse events due to the reduced level of all 4 drugs. To design this study, we previously performed a proof-of-concept pilot study with 24 patients and observed a reduction in acute rejection rate (50 vs 10%, p= 0.001) and lower levels of CMV viremia in the quadruple group compared to the triple therapy group. The aim of this study is to develop a clinical trial with a planned sample size for the primary objective and at the same time analyze some mechanisms (anti-HLA antibodies dynamics, CMV-specific T-cell immunity, differences in peripheral lymphocyte sub-populations, genes expressions in renal biopsies and the correlations of pharmacokinetics of these drugs with all events) involved in the observed efficacy of the pilot study. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list using this form.